Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of "Buy" from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $26.60.

ATXS has been the subject of several recent research reports. Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. JMP Securities initiated coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 price objective for the company. Wedbush restated an "outperform" rating and set a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th.

Hedge Funds Weigh In On Astria Therapeutics

Several large investors have recently bought and sold shares of ATXS. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 5,798 shares during the period. Intech Investment Management LLC bought a new position in Astria Therapeutics during the third quarter valued at about $228,000. Charles Schwab Investment Management Inc. increased its stake in Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock valued at $3,460,000 after acquiring an additional 189,727 shares during the period. FMR LLC raised its holdings in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock valued at $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Astria Therapeutics in the 3rd quarter worth approximately $613,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Astria Therapeutics stock traded up $0.12 during trading hours on Friday, hitting $5.52. The company had a trading volume of 53,461 shares, compared to its average volume of 270,761. The firm has a market capitalization of $311.52 million, a P/E ratio of -2.64 and a beta of 0.69. The firm's fifty day moving average is $6.72 and its 200-day moving average is $9.05. Astria Therapeutics has a fifty-two week low of $5.24 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. Analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.